No profile data available.
Anavex Life Sciences Corp. (AVXL) is a healthcare company in the brain and nerve treatment drugs industry, based in New York, United States, with about 34 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$46.38 million. In Q3 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $138.12 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer .
Anavex Life Sciences reported $0 in revenue for fiscal year 2025. In Q3 2026 revenue was $0.
$138.12 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Acumen Pharmaceuticals, Inc. (ABOS), Minerva Neurosciences, Inc. (NERV), Voyager Therapeutics, Inc. (VYGR), Tonix Pharmaceuticals Holding Corp. (TNXP).